10-Q: Merus N.V. Q3 2025: Genmab Acquisition & Clinical Progress

Merus N.V. reports Q3 2025 results, highlighting the pending Genmab acquisition offer, increased R&D spend on key oncology candidates, and a significant net loss, while maintaining a strong cash position into 2028.

Summary

• Genmab A/S (Purchaser) commenced a cash tender offer to acquire all issued and outstanding common shares of Merus N.V. for $97.00 per share, without interest and subject to any applicable tax withholding. The offer is set to expire on December 11, 2025.
• Net loss for the nine months ended September 30, 2025, was $350.2 million, a significant increase from $184.4 million for the same period in 2024.
• Total revenue for the nine months ended September 30, 2025, increased to $47.5 million, up from $27.0 million in 2024, driven by $13.4 million in commercial material revenue and a $6.8 million increase in collaboration revenue.
• Research and development (R&D) expenses rose substantially by $103.1 million to $254.0 million for the nine months ended September 30, 2025, primarily due to increased clinical trial support for petosemtamab.
• General and administrative (G&A) expenses increased by $16.5 million to $76.0 million for the nine months ended September 30, 2025.
• Cash, cash equivalents, and marketable securities totaled $816.8 million as of September 30, 2025, which is expected to fund operations at least into 2028.
• BIZENGRI (zenocutuzumab-zbco) received FDA accelerated approval for NRG1+ pancreatic adenocarcinoma or NSCLC, with commercialization exclusively licensed to Partner Therapeutics, Inc. (PTx) in the United States.
• PTx announced FDA Breakthrough Therapy designation for zenocutuzumab-zbco (BIZENGRI) for the treatment of adults with advanced, unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion in October 2025.
• Interim clinical data for petosemtamab in combination with pembrolizumab for 1L PD-L1+ r/m HNSCC showed a 63% confirmed overall response rate and 79% overall survival rate at 12 months.
• Interim clinical data for petosemtamab with FOLFOX/FOLFIRI in 1L mCRC showed an 80% response rate (90% in left-sided mCRC).
• Ongoing legal proceedings include a patent infringement complaint against Xencor, Inc., where the Court granted Xencor's motion to dismiss (with leave to amend), and the PTAB instituted IPRs for two patents.

Sentiment

Score: 8

Explanation: The pending acquisition by Genmab at a significant premium of $97.00 per share is a highly positive development for shareholders, providing a clear and attractive liquidity event. This outweighs the increased net losses and R&D expenses, which are typical for a clinical-stage biotech. Positive interim clinical data and a new Breakthrough Therapy designation further support the underlying value of the company's pipeline.

Positives

• Genmab's cash tender offer of $97.00 per common share provides a clear exit strategy and potential premium for shareholders.
• Total revenue increased significantly to $47.5 million for the nine months ended September 30, 2025, up from $27.0 million in the prior year, driven by commercial material revenue and increased collaboration revenue.
• A strong cash position of $816.8 million (cash, cash equivalents, and marketable securities) as of September 30, 2025, is projected to fund operations at least into 2028.
• BIZENGRI (zenocutuzumab-zbco) received FDA accelerated approval for NRG1+ pancreatic adenocarcinoma or NSCLC, validating the company's Biclonics platform.
• Partner Therapeutics, Inc. (PTx) announced FDA Breakthrough Therapy designation for zenocutuzumab-zbco (BIZENGRI) for cholangiocarcinoma harboring an NRG1 gene fusion in October 2025, indicating further clinical validation and market potential.
• Positive interim clinical data for petosemtamab in combination with pembrolizumab for 1L PD-L1+ r/m HNSCC, showing a 63% confirmed overall response rate and 79% overall survival rate at 12 months.
• Encouraging interim clinical data for petosemtamab with FOLFOX/FOLFIRI in 1L metastatic colorectal cancer (mCRC), showing an 80% response rate (90% in left-sided mCRC).
• LiGeR-HN1 and LiGeR-HN2 Phase 3 trials for petosemtamab are enrolling and expected to be substantially enrolled by year-end 2025, with potential top-line interim readout in 2026.

Negatives

• Net loss significantly increased to $350.2 million for the nine months ended September 30, 2025, compared to $184.4 million in the prior year.
• Research and development (R&D) expenses increased by $103.1 million to $254.0 million for the nine months ended September 30, 2025, contributing to the increased net loss.
• General and administrative (G&A) expenses increased by $16.5 million to $76.0 million for the nine months ended September 30, 2025.
• Foreign exchange losses significantly impacted other income (loss), net, resulting in a loss of $78.3 million for the nine months ended September 30, 2025, compared to a loss of $16.9 million in the prior year.
• The company has an accumulated deficit of $1,318.6 million as of September 30, 2025, and expects to continue incurring significant operating losses for the foreseeable future.
• Ongoing patent infringement litigation with Xencor, Inc., including the Court granting Xencor's motion to dismiss (with leave to amend) and the PTAB instituting IPRs for two patents, indicates potential legal costs and uncertainty.

Risks

• The proposed Genmab acquisition may not be completed within the expected timeframe or at all, which could adversely affect the business, and the company is subject to restrictions during the interim period.
• The company has incurred significant net losses since inception and expects to continue incurring significant expenses and operating losses for the foreseeable future.
• Substantial additional capital will be required to finance operations if the Genmab acquisition does not close, with potential delays or elimination of research and drug development programs if capital is unavailable.
• The outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and results may not satisfy regulatory requirements.
• The clinical trial and regulatory approval processes are lengthy, time-consuming, inherently unpredictable, and may incur additional costs or delays.
• Antibody candidates may have serious adverse, undesirable, or unacceptable side effects, which may delay or prevent marketing approval or limit the commercial profile.
• The company has limited experience with registrational clinical trials and commercializing an antibody candidate independently, relying on an exclusive licensee for its single approved product.
• Inability to successfully manufacture product candidates in sufficient quality and quantity could delay or prevent development and commercialization.
• Reliance on third parties, including independent clinical investigators and contract research organizations (CROs), to conduct pre-clinical studies and clinical trials poses risks if they do not successfully carry out duties or meet deadlines.
• Decisions to prioritize development of certain antibody candidates over others due to limited resources may prove wrong and adversely affect revenues.
• Intense competition for qualified personnel in the biopharmaceutical industry.
• Operating in highly competitive and rapidly changing industries, where competitors may develop more effective, safer, or less expensive products.
• Dependence on the ability to protect intellectual property and proprietary technologies; failure to do so could lead to direct competition.
• Reliance on existing collaboration and license agreements; inability to maintain or execute new collaborations could adversely affect the business.
• High volatility in stock prices due to global economic disruptions, including rising inflation, interest rates, and geopolitical conflicts, impacting the ability to raise capital.
• Failure to maintain accelerated approval for zenocutuzumab due to an inability to verify clinical benefit in confirmatory trials or non-compliance with post-marketing requirements.
• Potential for costly and damaging liability claims and reputational risks from testing or commercializing antibody candidates, with product liability insurance potentially not covering all damages.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, with no guarantee of approval for other antibody candidates.
• Fast Track or Breakthrough Therapy designations may not actually lead to faster development or approval.
• Ongoing obligations and continued regulatory review for approved products, potentially resulting in significant additional expense, labeling restrictions, or market withdrawal.
• Failure to obtain orphan drug designation or maintain orphan drug exclusivity could lead to competition and reduced revenue.
• Uncertainty regarding insurance coverage and reimbursement for newly approved products, potentially limiting market access and revenue generation.
• Limited marketing, sales, or distribution infrastructure, requiring significant investment or successful collaborations for commercialization.
• Potential for biosimilar competition sooner than anticipated for biologic products, shortening market exclusivity.
• Risks associated with international operations, including economic weakness, political instability, differing regulatory requirements, and foreign currency fluctuations.
• Risks from improper conduct by employees, agents, contractors, or collaborators, including noncompliance with healthcare, anti-corruption, and privacy laws.
• Research and development activities could be affected or delayed by restrictions on animal testing.
• Information technology systems or those of third parties may fail or suffer security breaches, leading to loss of data, intellectual property, or personal information, and potential liabilities.
• Difficulty in managing growth due to expansion in employees and operations.
• Future sales, or the possibility of future sales, of a substantial number of common shares could adversely affect the share price.
• Provisions in articles of association or Dutch corporate law might deter acquisition bids.
• Holders of common shares outside the Netherlands may not be able to exercise preemptive rights.
• The rights of shareholders may be different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions.
• Non-compliance with all best practice provisions of the Dutch Corporate Governance Code may affect shareholder rights.
• Claims of U.S. civil liabilities may not be enforceable against the company.
• A U.S. federal forum selection clause could limit shareholders' ability to obtain a favorable judicial forum.
• Potential classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. investors.
• If a U.S. Holder owns at least 10% of common shares, such holder may be subject to adverse U.S. federal income tax consequences as a United States shareholder of a controlled foreign corporation.
• The price of common shares may be volatile and may fluctuate due to factors beyond control.
• Unstable market and economic conditions may have serious adverse consequences on business, financial condition, and share price.
• Business interruptions (e.g., fire, severe weather, public health crises) could adversely affect operations.
• No expectation of cash dividends for the foreseeable future; returns on investment will likely depend entirely upon future appreciation in the price of common shares.
• Inaccurate or unfavorable research by securities or industry analysts could cause the share price and trading volume to decline.
• Increased costs and management time due to operating as a public company, especially after no longer qualifying as an emerging growth company or smaller reporting company.
• Varied and differing positions on environmental sustainability and social initiatives by governments and other stakeholders could increase costs, harm reputation, and adversely impact financial results.

Future Outlook

Merus N.V. expects its existing cash, cash equivalents, and marketable securities of $816.8 million as of September 30, 2025, to fund operations at least into 2028. The company anticipates continued significant expenses and operating losses as its antibody candidates advance through discovery, pre-clinical development, clinical trials, and potential commercialization. The LiGeR-HN1 and LiGeR-HN2 Phase 3 trials for petosemtamab are expected to be substantially enrolled by year-end 2025, with potential top-line interim readouts in 2026. The proposed acquisition by Genmab, if completed, will result in Merus becoming an indirect wholly-owned subsidiary, leading to delisting from Nasdaq and cessation of SEC reporting obligations. The evolving EU pharmaceutical legislation, with revisions not expected to be applicable before late 2026-2027, may significantly impact the biopharmaceutical industry and Merus's business in the long term.

Management Comments

• We expect to continue to incur significant expenses and operating losses for the foreseeable future as our antibody candidates advance through discovery, pre-clinical development and clinical trials and as it seeks regulatory approval and pursues commercialization of any approved antibody candidate.
• Based on our current operating plan, we expect that our existing cash, cash equivalents and marketable securities of $816.8 million as of September 30, 2025 will fund our operations at least into 2028.
• We believe a randomized registration trial in HNSCC with an overall response rate endpoint could potentially support accelerated approval and the overall survival results from the same study could potentially verify its clinical benefit to support regular approval for the Company’s LiGeR-HN1 and LiGeR-HN2 trials.
• We remain interested in exploring partnering MCLA-129 to sufficiently resource the development of MCLA-129 and the potential benefit it may have for patients.

Industry Context

The biopharmaceutical industry is highly competitive and characterized by rapid technological change, with Merus N.V. facing intense competition from large pharmaceutical companies, specialty biopharmaceutical firms, academic institutions, and government agencies. The industry is also navigating increasing governmental scrutiny over drug pricing, with recent U.S. legislation like the Inflation Reduction Act of 2022 and the One Big Beautiful Bill Act potentially impacting Medicare and Medicaid programs, leading to reduced demand and increased pricing pressures. In Europe, the regulatory landscape is evolving with the new Clinical Trials Regulation (CTR) and ongoing revisions to pharmaceutical legislation, which could affect development timelines and operating costs. The oncology market, in particular, demands continuous innovation, and companies like Merus N.V. must adapt to these dynamic regulatory and competitive environments while managing significant R&D investments.

Management Changes

Corporate Governance

Legal Proceedings

• Merus N.V. filed a complaint on August 5, 2024, in the U.S. District Court of Delaware against Xencor, Inc., alleging infringement of U.S. Patent Nos. 9,944,695, 9,358,268, and 11,926,859. The Court granted Xencor's motion to dismiss on September 30, 2025, with leave for Merus to file an amended complaint by November 11, 2025.
• Xencor, Inc. filed two petitions for inter partes review (IPR) before the Patent Trial and Appeal Board (PTAB) on February 11, 2025, challenging U.S. Patent Nos. 9,358,268 and 11,926,859. The PTAB instituted the IPRs on September 26, 2025.
• Kymab Limited filed a notice of opposition against Merus's EP3456190 patent in the European Opposition Division of the European Patent Office (EPO) on August 19, 2022. The European Opposition Division maintained the patent as granted on January 18, 2024. Kymab filed a notice of appeal in April 2024, with oral proceedings scheduled for July 9, 2026.

Related Party Transactions

• Collaboration, option, and license agreement with Gilead Sciences, Inc. (Gilead) entered into on March 5, 2024, for the development of trispecific T-cell engaging multi-specific antibody products.
• License agreement with Partner Therapeutics, Inc. (PTx) entered into on November 27, 2024, granting PTx exclusive rights to commercialize zenocutuzumab for NRG1+ cancer in the United States.
• Research collaboration and license agreement with Biohaven Ltd. entered into on January 12, 2025, to co-develop three novel bispecific antibody drug conjugates (ADCs).
• Collaboration and license agreement with Eli Lilly and Company (Lilly) entered into on January 18, 2021, for the discovery and research of bispecific antibodies.
• Collaboration and license agreement with Incyte Corporation (Incyte) completed on January 23, 2017, for the sale of shares and exchange of a license.
• License agreements with Ono Pharmaceutical Co., Ltd. (Ono) granted in April 2014 and March 14, 2018, for the development of bispecific antibody candidates.

Stakeholder Impact

• **Shareholders**: Highly positive impact due to the Genmab acquisition offer at $97.00 per share, providing a substantial premium and a clear liquidity event. Potential for dilution if the acquisition fails and future capital raises are needed.
• **Employees**: Uncertainty regarding the effect of the Genmab acquisition on employment, which could impact the company's ability to attract and retain key personnel.
• **Customers/Patients**: Continued development of innovative antibody therapeutics, with BIZENGRI already approved and other candidates showing promising clinical data, potentially offering new treatment options for various cancers.
• **Collaborators/Partners**: Existing collaborations (Incyte, Lilly, Gilead, Biohaven, Betta Pharma, PTx) are crucial for development and commercialization, with risks if these relationships are not maintained or if partners fail to perform.
• **Creditors**: The strong cash position and potential acquisition provide stability, but ongoing operational losses and capital requirements if the acquisition fails could pose risks.

Next Steps

• Completion of the Genmab tender offer by December 11, 2025, followed by a subsequent offering period and back-end reorganization transactions.
• Delisting of common shares from Nasdaq and deregistration under the Exchange Act, if the Genmab acquisition closes.
• Substantial enrollment of LiGeR-HN1 and LiGeR-HN2 Phase 3 trials by year-end 2025.
• Potential top-line interim readout for LiGeR-HN1 and LiGeR-HN2 trials in 2026.
• Filing an amended complaint in the Xencor patent litigation by November 11, 2025.
• Oral proceedings for Kymab appeal against EP3456190 patent scheduled for July 9, 2026.
• Continued investigation of MCLA-129 in MET ex14 NSCLC and in combination with chemotherapy in 2L+ EGFRm NSCLC.
• Ongoing translational work on potential biomarkers outside of NRG1+ cancer for zenocutuzumab.
• Evaluation of the full effects of the One Big Beautiful Bill Act on estimated annual effective tax rate and cash tax position.
• Monitoring and evaluation of patients in ongoing clinical trials for petosemtamab and MCLA-129.

Key Dates

Recommendation

The Genmab acquisition offer of $97.00 per share represents a significant premium over recent trading prices and provides a high-certainty, near-term liquidity event for shareholders. This offer, combined with the underlying value of the company's oncology pipeline, including the FDA-approved BIZENGRI and promising clinical data for petosemtamab, makes the stock a strong buy for investors seeking a defined exit at a favorable valuation. The operational losses and increased R&D expenses are typical for a biotech at this stage and are largely mitigated by the acquisition offer.

Keywords

Oncology, Antibody Therapeutics, Bispecific Antibodies, Trispecific Antibodies, ADClonics, Merus N.V., Genmab, Acquisition, Clinical Trials, Petosemtamab, MCLA-158, Zenocutuzumab, BIZENGRI, MCLA-128, MCLA-129, NRG1 Fusion Cancer, HNSCC, mCRC, NSCLC, FDA Approval, Breakthrough Therapy, Research and Development, Financial Results, SEC Filing, 10-Q, Biopharmaceutical, Patent Litigation, Intellectual Property